ERAS Clinical Trials

8 recruiting

ERAS Trials at a Glance

22 actively recruiting trials for eras are listed on ClinicalTrialsFinder across 6 cities in 21 countries. The largest study group is Not Applicable with 9 trials, with the heaviest enrollment activity in Chicago, Philadelphia, and Barcelona. Lead sponsors running eras studies include Inozyme Pharma, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh, and Aristotle University Of Thessaloniki.

Browse eras trials by phase

Treatments under study

About ERAS Clinical Trials

Looking for clinical trials for ERAS? There are currently 8 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new ERAS trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about ERAS clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 22 trials

Recruiting
Not Applicable

The Effect of the Cesarean ERAS Protocol on Mother-Infant and Father-Infant Bonding: a Multicenter, Randomized Controlled Clinical Trial.

ERASCesarean SectionBonding+1 more
Okan University1 enrolled1 locationNCT07276126
Recruiting
Not Applicable

Pre-operative Risk Assessment Combined With Targeted Intervention in the Chinese Elderly With Spine Surgery II

PrehabilitationFrail ElderlyLumbar Degenerative Disease+2 more
Xuanwu Hospital, Beijing248 enrolled4 locationsNCT07396077
Recruiting
Phase 1Phase 2

An Open-label Study to Investigate ECUR-506 in Male Babies Less Than 9 Months of Age With Neonatal Onset OTC Deficiency

Ornithine Transcarbamylase DeficiencyOrnithine Transcarbamylase Deficiency DiseaseUrea Cycle Disorders, Inborn+1 more
iECURE, Inc.20 enrolled12 locationsNCT06255782
Recruiting
Not Applicable

Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer

Breast CancerMastectomyPrepectoral Breast Reconstruction+1 more
University of Rome Tor Vergata100 enrolled1 locationNCT07510698
Recruiting
Phase 1

The ENERGY Study: Evaluation of Safety and Tolerability of INZ-701 in Infants With ENPP1 Deficiency or ABCC6 Deficiency

Pseudoxanthoma ElasticumEctonucleotide Pyrophosphatase/phosphodiesterase1 DeficiencyAutosomal Recessive Hypophosphatemic Rickets+2 more
Inozyme Pharma16 enrolled7 locationsNCT05734196
Recruiting
Phase 3

ENERGY 2: Evaluation of the Efficacy and Safety of INZ-701 in Infants With ENPP1 Deficiency

Ectonucleotide Pyrophosphatase/phosphodiesterase1 DeficiencyAutosomal Recessive Hypophosphatemic RicketsGeneralized Arterial Calcification of Infancy 1
Inozyme Pharma12 enrolled8 locationsNCT07473973
Recruiting

Real-life Ecological Momentary Assessment of Lived Burden in Hereditary AngioEdema

Hereditary Angioedema With C1 Esterase Inhibitor DeficiencyHereditary Angioedema - Type 1Hereditary Angioedema - Type 2
Istituti Clinici Scientifici Maugeri SpA30 enrolled1 locationNCT07448181
Recruiting
Phase 4

Impact of ERAS Protocol on Length of Hospital Stay After Laparoscopic Surgeries

ERAS
Aga Khan University98 enrolled1 locationNCT07116564
Recruiting

PROPEL - A Prospective Observational Patient Registry to Evaluate ENPP1 and ABCC6 Deficiency

ATP-Binding Cassette Subfamily C Member 6 DeficiencyEctonucleotide Pyrophosphatase/Phosphodiesterase 1 Deficiency
Inozyme Pharma1,000 enrolled14 locationsNCT06302439
Recruiting
Not Applicable

Impact of a Technology Platform Based on Enhanced Recovery After(ERAS) Surgery on Length of Stay After Coronary Artery Bypass Grafting: Timely Project

Digital HealthERASCardiac Surgery+1 more
University of Sao Paulo General Hospital480 enrolled2 locationsNCT06786819
Recruiting
Not Applicable

Pre-habilitation Within ERAS Protocol for Gynecologic Oncology Surgery: The Pre_ERAS Study

Quality of Life (QOL)Post Operative PainSurgical Complication+8 more
Aristotle University Of Thessaloniki100 enrolled1 locationNCT07210164
Recruiting
Phase 4

Erector Spinae Block in Reducing Peri-operative Opioid Consumption in Total Abdominal Hystrectomy

Erector Spinae BlockOpioidEnhanced Recovery After Surgery (ERAS) Protocol
Kulsoom International Hospital60 enrolled1 locationNCT07178262
Recruiting

A Natural History Study Seeks to Understand the Clinical, Genomic, Pharmacological, Laboratory, and Dietary Determinates of Pyrimidine and Purine Metabolism Disorders

Metabolic DiseaseAMPD3, OMIM*102772, AMP Deaminase DeficiencyAK1, OMIM *103000, Adenylate Kinase Deficiency+25 more
National Human Genome Research Institute (NHGRI)999 enrolled1 locationNCT06092346
Recruiting
Not Applicable

Enhanced Recovery After Surgery(ERAS) Following Gynaecological Oncology Surgery in a Tertiary Level Hospital

CancerERAS
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh130 enrolled1 locationNCT07087366
Recruiting

Prospective Research Rare Kidney Stones (ProRKS)

Adenine Phosphoribosyltransferase DeficiencyCystinuriaDent Disease+2 more
Mayo Clinic220 enrolled11 locationsNCT02780297
Recruiting
Phase 2

Brachytherapy (Iodine-125 Seeds) and Fluzoparib Combination Therapy for Advanced Unresectable Soft Tissue Sarcoma

Sarcoma,Soft TissueBrachytherapyPoly(ADP-ribose) Polymerase Inhibitors
Fujun Zhang32 enrolled1 locationNCT05894018
Recruiting

Compliance With ERAS Protocol in Pancreatic Surgery, Stress Response and Outcomes

Pancreas CancerERASPancreas; Fistula+1 more
University of Thessaly120 enrolled1 locationNCT05518643
Recruiting
Not Applicable

Effect of Enhanced Recovery After Surgery for Benign Anorectal Conditions

HaemorrhoidAnal FistulaEnhanced Recovery After Surgery (ERAS) Protocol+1 more
Mansoura University100 enrolled1 locationNCT06803550
Recruiting
Not Applicable

Patient Reported Outcomes Targeting Early Chest Tube Removal (PROTECTR) Study

Lung SurgeryChest Tube RemovalEnhanced Recovery After Surgery (ERAS)
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's130 enrolled1 locationNCT06444854
Recruiting

Enhanced Recovery Protocols in Gynecologic Oncology

Quality of LifeGynecologic CancerPostoperative Pain+3 more
National and Kapodistrian University of Athens600 enrolled8 locationsNCT06655506